My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
BSE: 532300 | NSE: WOCKPHARMA | Pharmaceuticals & Drugs | Small Cap
1. Is Wockhardt Ltd a good quality company?
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Wockhardt Ltd is a below average quality company.
2. Is Wockhardt Ltd undervalued or overvalued?
The key valuation ratios of Wockhardt Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Wockhardt Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Wockhardt Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |||
| ROCE % ⓘ | 13.3% | 8.8% | 5.5% | -0.8% | -3.6% | -1.3% | 0.2% | -1.5% | 1.4% | -3.8% | - | ||
| Value Creation Index ⓘ | -0.1 | -0.4 | -0.6 | -1.1 | -1.3 | -1.1 | -1.0 | -1.1 | -0.9 | -1.3 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 4,830 | 4,482 | 4,453 | 4,015 | 3,937 | 3,566 | 2,844 | 2,708 | 3,230 | 2,651 | 2,700 | ||
| YoY Gr. Rt. % | - | -7.2% | -0.6% | -9.9% | -1.9% | -9.4% | -20.2% | -4.8% | 19.3% | -17.9% | - | ||
| Adj EPS ⓘ | 53.3 | 39.2 | 21.8 | -17.9 | -37.1 | -22.6 | -14.9 | -22 | -8.6 | -29.8 | -43.5 | ||
| YoY Gr. Rt. % | - | -26.6% | -44.3% | -182.1% | NA | NA | NA | NA | NA | NA | - | ||
| BVPS (₹) ⓘ | 271.8 | 282.2 | 312.4 | 275.1 | 234.5 | 220 | 219.8 | 280.5 | 266 | 231.8 | 222.2 | ||
| Adj Net Profit ⓘ | 635 | 468 | 261 | -215 | -445 | -272 | -179 | -265 | -124 | -430 | -627 | ||
| Cash Flow from Ops. ⓘ | 1,476 | 355 | 71.6 | -269 | 68.4 | 183 | 649 | -287 | 413 | 153 | - | ||
| Debt/CF from Ops. ⓘ | 1.3 | 5.7 | 37.4 | -15.4 | 54.8 | 18.4 | 5 | -8.1 | 4.5 | 12.3 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | -6.5% | -7.6% | -2.3% | -17.9% | ||||||||
| Adj EPS ⓘ | -193.8% | NA | NA | NA | ||||||||
| BVPSⓘ | -1.8% | -0.2% | 1.8% | -12.9% | ||||||||
| Share Price | -6.4% | -13.9% | -5.5% | -3.5% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | ||
| Return on Equity % ⓘ | 20.2 | 12.8 | 7 | -6 | -14.4 | -9.8 | -6.7 | -8.8 | -3.4 | -11.9 | -19.2 | |
| Op. Profit Mgn % ⓘ | 20.3 | 18.5 | 11.4 | 0.7 | -1.4 | -0.4 | 3.4 | -2.3 | 9.2 | 3.8 | 5 | |
| Net Profit Mgn % ⓘ | 16.1 | 10.6 | 5.9 | -6.1 | -12.8 | -8.3 | -5.4 | -9.7 | -4.9 | -18.5 | -23.2 | |
| Debt to Equity ⓘ | 0.5 | 0.6 | 0.7 | 1.3 | 1.3 | 1.3 | 1.2 | 0.7 | 0.5 | 0.6 | - | |
| Working Cap Days ⓘ | 164 | 192 | 223 | 242 | 233 | 255 | 320 | 186 | 166 | 188 | 0 | |
| Cash Conv. Cycle ⓘ | 67 | 68 | 99 | 134 | 116 | 114 | 130 | 37 | 10 | -7 | 0 | |
Debt to equity has declined versus last 3 years average to 0.57
Return on Equity is Poor
Sales growth has been subdued in last 3 years -2.32%
Sales growth is not so good in last 4 quarters at -6.91%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | -37.8 | -43.5 |
| TTM Sales (₹ Cr.) | 1,082 | 2,700 |
| BVPS (₹.) ⓘ | 112.6 | 222.2 |
| Reserves (₹ Cr.) ⓘ | 1,550 | 3,130 |
| P/BV ⓘ | 2.09 | 1.06 |
| PE ⓘ | 0.00 | 0.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 145.35 / 269.05 |
| All Time Low / High (₹) | 62.20 / 1996.06 |
| Market Cap (₹ Cr.) | 3,390 |
| Equity (₹ Cr.) | 72.1 |
| Face Value (₹) | 5 |
| Industry PE ⓘ | 42.8 |
| Pledged * | 18.71 | 34.44 | 41.99 | 47.32 | 43.60 | 47.84 | 52.77 | 56.08 | 65.46 | 69.08 |
Wockhardt Ltd. is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. It is a true Indian Multi-National Company with a multi-ethnic workforce of many Wockhardt Associates from many different nationalities globally. It has many research centres and several manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. It is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process and techno-innovation within Wockhardt.
Business area of the company
The company is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.
Awards
2009
2010
2011
2012
2013
2015
2016
2017
2018
2019
2020
Milestones
2010
2011
2012
2013
2014
2015
2018
2019
2020
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
